Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Jasper Therapeutics, Inc. (JSPR)

Jasper Therapeutics completes IgAN enrollment for vensobafusp alfa; interim data by year-end 2026

Neutral Impact 3 of 5 product/contract Written later

Jasper Therapeutics said it has completed enrollment of the IgA nephropathy cohort of its Phase 2 basket study of vensobafusp alfa (KP104), with 18 patients enrolled in stage 1. The company expects initial interim data from the IgAN cohort by year-end 2026 and has added an FSGS cohort, with first dosing anticipated in the first quarter of 2027. The filing contains no financial results, so the update is a clinical development milestone rather than a change in reported financial measures.

Key points

  • Enrollment completed in the IgAN cohort: 18 patients across 3 cohorts (Q2W, Q4W and Q8W maintenance, six patients each)
  • Initial interim data from the IgAN basket study expected by year-end 2026
  • FSGS expansion cohort added, with first patient anticipated to be dosed in the first quarter of 2027

The filing

CompanyJasper Therapeutics, Inc. (JSPR)
Form8-K, current report
Filed with the SECOct 15, 2026, 8:00 AM ET
Accession number0001213900-26-109587

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 15, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.